";s:4:"text";s:4992:"has a consultant/advisory relationship with Celgene and Millenium and has received research funding from Millenium. has received honoraria from Celgene and Amgen. has received honoraria from Celgene.
Time-to-progression (median 48.3 vs. 27.5 months, P = 0.071), and progression-free survival (median 48.3 vs. 27.5 months, P = 0.044) were higher with BiRd. J. L. consultancy for Celgene. J. L. consultancy for Celgene. A.K.S. Infections (16.7% vs. 9.7%, P = 0.218) and dermatological toxicity (12.5% vs. 4.2%, P = 0.129) were higher with Rd. Steroids cause a wide range of side effects, affecting nearly every system of the body. M.A.G has received honoraria from Celgene, Millenium, Genzyme and Amgen. M.Q.L., A.D., T.E.W, have received research funding/grants from Celgene. has received honoraria from Celgene, Millenium and Onyx, has a consultant/advisory relation with Celgene, Millenium and Onyx and has received research funding from Celgene. has received honoraria from Celgene. has a consultant/advisory relationship with Celgene and Millenium and has received research funding from Millenium. has received research funding from Celgene and honoraria from Celgene and Millenium.
M.A.G has received honoraria from Celgene, Millenium, Genzyme and Amgen. has received honoraria from Celgene, Millenium and Onyx, has a consultant/advisory relation with Celgene, Millenium and Onyx and has received research funding from Celgene. If this benefit is related to the optimization of the steroid effects or to a direct antineoplastic activity it is still unknown.The AEs reported were consistent with the established toxicity profile for both regimens. T.M. The remaining authors declare no conflict of interest.Division of Hematology and Medical Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill‐Cornell Medical College, New York Presbyterian Hospital‐Cornell Medical Center, New York, New YorkConflict of Interest: F.G. has received honoraria from Celgene. T.M. has received honoraria from Celgene. M.Q.L., A.D., T.E.W, have received research funding/grants from Celgene. conceived the treatment program, wrote and implemented the protocol, coordinated data and database, coordinated input from all the authors, conceived the figures, and wrote the manuscript; D.S.J. and John Leonard and Lacy, {Martha Q.} The combination of clarithromycin, lenalidomide and dexamethasone (BiRd) has led to highly durable responses in newly diagnosed myeloma. Median OS is provided in the figure (m: months). P.R.G. provided expert analysis of immunoprotein analysis; H.J.C. Despite a higher rate of Grade 3–4 AEs, treatment discontinuation due to AEs was similar in both groups. Mean time to clarithromycin dose reduction level 1 was 178 days (range, 53-331 days), and mean time to clarithromycin discontinuation was 300 days (range, 290-309 days).The relative dose intensity (RDI) for lenalidomide, dexamethasone, and clarithromycin is shown in The novel combination of clarithromycin, lenalidomide, and dexamethasone (BiRD) in this phase 2 trial for treatment-naive, symptomatic MM showed a 90.3% ORR, with a combined sCR and CR rate of 38.9%. J. L. consultancy for Celgene. has a consultant/advisory relationship with Celgene and Millenium and has received research funding from Millenium. consultancy for Celgene, Medtronic, Genzyme, Amgen, Bristol‐Myers Squibb, Otsuka American Pharmaceutical. Major toxic effects were thromboembolic events (12.5%), corticosteroid related morbidity (in particular myopathy in 11.1% of patients) and cytopenia (neutropenia in 19.4% of patients and thrombocytopenia in 22.2% [No comparative study of Rd vs BiRd has been reported so far and none are ongoing or planned.